February 22, 2016 8:31am
MESO results have shown that use of its Tier 1 mesenchymal stem cell product candidate remestemcel-L demonstrated clinically meaningful responses and significantly increased survival in children with steroid-refractory acute Graft Versus Host Disease - BUY
Members only. Please login.